C12N 2710/16222
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16222 (New viral proteins or individual genes, new structural or functional aspects of) appears on 246 US grants and 200 published applications in this corpus.
Search patents in C12N- Granted patents
- 246
- Published applications
- 200
- Assignees
- 192
- Inventors
- 488
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 8 | 0 |
| 1995 | 8 | 0 |
| 1996 | 6 | 0 |
| 1997 | 11 | 0 |
| 1998 | 27 | 0 |
| 1999 | 8 | 0 |
| 2000 | 18 | 0 |
| 2001 | 9 | 2 |
| 2002 | 14 | 9 |
| 2003 | 9 | 9 |
| 2004 | 9 | 13 |
| 2005 | 3 | 8 |
| 2006 | 6 | 9 |
| 2007 | 4 | 9 |
| 2008 | 9 | 5 |
| 2009 | 2 | 9 |
| 2010 | 6 | 4 |
| 2011 | 7 | 10 |
| 2012 | 2 | 8 |
| 2013 | 6 | 8 |
| 2014 | 5 | 5 |
| 2015 | 3 | 7 |
| 2016 | 4 | 7 |
| 2017 | 5 | 5 |
| 2018 | 6 | 8 |
| 2019 | 7 | 4 |
| 2020 | 4 | 9 |
| 2021 | 7 | 6 |
| 2022 | 4 | 5 |
| 2023 | 5 | 14 |
| 2024 | 8 | 10 |
| 2025 | 4 | 11 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TCR constructs specific for EBV-derived antigens16 Jun 2026US 12,655,191 B2Max-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft
- LMP-1 expressing cells and methods of use thereof7 Apr 2026US 12,595,285 B2Dana-Farber Cancer Institute, Inc.
- Adeno-associated virus (AAV) producer cell lines9 Sep 2025US 12,410,436 B2Lonza Houston, Inc.
- Multivalent Epstein-Barr virus-like particles and uses thereof20 May 2025US 12,303,559 B2City of Hope
- Epstein-Barr Virus antigen constructs1 Apr 2025US 12,264,179 B2Glaxosmithkline Biologicals SA
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Function-enhanced engineered ebna1 for protein expression in mammalian cells27 Aug 2026US 2026/0250327 A1Wuxi Biologics Ireland Limited
- New peptides and use thereof as delivery systems for internalization of molecules of interest into target cells9 Jul 2026US 2026/0193297 A1Centre National De La Recherche Scientifique
- Immunogenic compositions for epstein-barr virus proteins30 Apr 2026US 2026/0115277 A1Merck Sharp & Dohme Corp.
- Vector for multi-gene base editing, editing method, and use16 Apr 2026US 2026/0103724 A1Agricultural Genomics Institute At Shenzhen, Chinese Academy of Agricultural Sciences
Most cited
By later US patents
- Production of recombinant adeno-associated virus vectors369US 5,173,414 AApplied Immune Sciences, Inc. · 1992
- Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse211US 4,879,213 AScripps Clinic and Research Foundation · 1989
- Targeted transfection nanoparticles172US 5,460,831 AThe Regents of the University of California · 1995
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998